Does curcumin delay time to prostate cancer recurrence in men on IADT?

The results of a small, randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients already treated on intermittent androgen deprivation therapy (IADT) have recently been published. … READ MORE …

IADT — pro and con; a follow-up

The other day we mentioned two articles in a recent issue of JAMA Oncology that dealt with the role of intermittent androgen deprivation therapy (IADT) in the management of progressive prostate cancer today. We have now had the good fortune to be able to read both of the two articles in full, thanks to a kind correspondent. … READ MORE …

Intermittent vs. continuous chemotherapy for men with CRPC

One of the small number of major prostate cancer presentations at the ASCO meeting this year comes from the so-called PRINCE trial of intermittent chemotherapy in men with castration-resistant prostate cancer (CRPC). … READ MORE …

CADT and IADT in the management of progressive and advanced prostate cancer

The debate over the relative values of continuous (CADT) and intermittent (IADT) forms of androgen deprivation therapy (ADT) in the treatment of advanced forms of prostate cancer has now been ongoing for years. … READ MORE …

Intermittent vs. continuous ADT: a therapeutic meta-analysis

According to the results from a new meta-analysis of data from 15 different clinical trials in nearly 7,000 patients in total, intermittent androgen deprivation therapy (ADT) is not inferior to continuous ADT with respect to the overall survival of patients. … READ MORE …

Intermittent vs. continuous ADT: the results of the ICELAND trial

The results of early, large, randomized trials of intermittent (IADT) vs. continuous androgen deprivation therapy (CADT) have provided conflicting results. However, one of the flaws in early trials was the failure to ensure that men enrolled into these trials all actually had an optimal initial response to androgen deprivation (ADT). … READ MORE …

IADT, dutasteride, and the AVIAS trial — not the result some would want to hear

So the initial results of the AVIAS trial are not going to make a couple of our regular readers too happy — although at least a trial of the type they have been asking for has now been carried out. … READ MORE …